Oryzon Genomics (Spain) Probability of Future Stock Price Finishing Over 1.62
| ORY Stock | EUR 1.56 0.01 0.64% |
Oryzon |
Oryzon Genomics Target Price Odds to finish over 1.62
The tendency of Oryzon Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over € 1.62 or more in 90 days |
| 1.56 | 90 days | 1.62 | about 92.68 |
Based on a normal probability distribution, the odds of Oryzon Genomics to move over € 1.62 or more in 90 days from now is about 92.68 (This Oryzon Genomics SA probability density function shows the probability of Oryzon Stock to fall within a particular range of prices over 90 days) . Probability of Oryzon Genomics SA price to stay between its current price of € 1.56 and € 1.62 at the end of the 90-day period is about 5.42 .
Assuming the 90 days trading horizon Oryzon Genomics SA has a beta of -0.34. This indicates as returns on the benchmark increase, returns on holding Oryzon Genomics are expected to decrease at a much lower rate. During a bear market, however, Oryzon Genomics SA is likely to outperform the market. Additionally Oryzon Genomics SA has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Oryzon Genomics Price Density |
| Price |
Predictive Modules for Oryzon Genomics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Oryzon Genomics SA. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Oryzon Genomics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Oryzon Genomics is not an exception. The market had few large corrections towards the Oryzon Genomics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Oryzon Genomics SA, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Oryzon Genomics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.15 | |
β | Beta against Dow Jones | -0.34 | |
σ | Overall volatility | 0.1 | |
Ir | Information ratio | -0.21 |
Oryzon Genomics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Oryzon Genomics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Oryzon Genomics SA can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Oryzon Genomics SA generated a negative expected return over the last 90 days | |
| Oryzon Genomics SA may become a speculative penny stock | |
| Net Loss for the year was (4.69 M) with profit before overhead, payroll, taxes, and interest of 9.87 M. | |
| Oryzon Genomics SA has accumulated about 29.11 M in cash with (3.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Roughly 18.0% of the company outstanding shares are owned by corporate insiders |
Oryzon Genomics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Oryzon Stock often depends not only on the future outlook of the current and potential Oryzon Genomics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Oryzon Genomics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 52.8 M |
Oryzon Genomics Technical Analysis
Oryzon Genomics' future price can be derived by breaking down and analyzing its technical indicators over time. Oryzon Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Oryzon Genomics SA. In general, you should focus on analyzing Oryzon Stock price patterns and their correlations with different microeconomic environments and drivers.
Oryzon Genomics Predictive Forecast Models
Oryzon Genomics' time-series forecasting models is one of many Oryzon Genomics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Oryzon Genomics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Oryzon Genomics SA
Checking the ongoing alerts about Oryzon Genomics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Oryzon Genomics SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Oryzon Genomics SA generated a negative expected return over the last 90 days | |
| Oryzon Genomics SA may become a speculative penny stock | |
| Net Loss for the year was (4.69 M) with profit before overhead, payroll, taxes, and interest of 9.87 M. | |
| Oryzon Genomics SA has accumulated about 29.11 M in cash with (3.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Roughly 18.0% of the company outstanding shares are owned by corporate insiders |
Other Information on Investing in Oryzon Stock
Oryzon Genomics financial ratios help investors to determine whether Oryzon Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oryzon with respect to the benefits of owning Oryzon Genomics security.